The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

FDA issues reminder to sponsors: Disclose clinical trial results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account